References
- AUA Practice Guidelines Committee. AUA Guideline on the management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003;170:530–47.
- Takei R, Ikegaki I, Shibata K, Tsujimoto G, Asano T. Naftopidil, a novel α1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human α1-adrenoceptors. Jpn J Pharmacol. 1999;79:447–54.
- McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, The long-term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:237–98.
- De la Rosette JJ, Kortmann BB, Rossi C, Sonke GS, Floratos DL, Kiemeney LA. Long-term risk of re-treatment of patients using alfa1-blockers for lower urinary tract symptoms. J Urol. 2002;167:1734–9.
- Masumori N, Hashimoto J, Itoh N, Tsukamoto T. Short-term efficacy and long-term compliance/treatment failure of the alpha1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Scand J Urol Nephrol. 2007;8:1–8.
- Ikemoto I, Kiyota H, Ohishi Y, Abe K, Goto H, Kishimoto K, Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative randomized two-drug crossover study. Int J Urol. 2003;10:587–94.
- Nishino Y, Masue T, Miwa K, Takahashi Y, Ishihara S, Deguchi T. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU Int. 2006;97:747–51.
- Gotoh M, Kamihira O, Kinukawa T, Ono Y, Ohshima S, Origasa H. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. BJU Int. 2005;96:581–6.
- Foster HE Jr, Yono M, Shin D, Takahashi W, Pouresmail M, Afiatpour P, Effects of chronic administration of doxazosin on alpha1-adrenoceptors in the rat prostate. J Urol. 2004;172:2465–70.
- Kojima Y, Sasaki S, Shinoura H, Hayashi Y, Tsujimoto G, Kohri K, Change of expression levels of alpha1-adrenoceptor subtypes by administration of alpha1d-adrenoceptor-subtype-selective antagonist naftopidil in benign prostate hyperplasia patients. Prostate. 2007;67:1285–92.
- Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, Natural history of prostatism: risk factors for acute urinary retention. J Urol. 1997;158:481–7.
- Emberton M, Elhilali M, Matzkin H, Harving N, van Moorselaar J, Hartung R, Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily. Urology. 2005;66:316–22.
- Cam K, Akman Y, Kayikci A, Senel F, Erol A. Short-term subjective efficacy of doxazosin in predicting probability of prostatectomy in the management of benign prostatic hyperplasia in patients with severe symptoms. Int J Urol. 2003;10:582–6.
- Hong SJ, Ko WJ, Kim SI, Chung BH. Identification of baseline clinical factors which predict medical treatment failure of benign prostatic hyperplasia: an observational cohort study. Eur Urol. 2003;44:94–100.
- de Nunzio C, Franco G, Rocchegiani A, Iori F, Leonardo C, Laurenti C. The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction. J Urol. 2003;169:535–9.